Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
grade B 11.14 -0.80% -0.09
CYTK closed down 0.8 percent on Friday, July 19, 2019, on 1.92 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical CYTK trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Three Weeks Tight Range Contraction 0.00%
MACD Bearish Signal Line Cross Bearish -0.80%
Bollinger Band Squeeze Range Contraction -0.80%
Upper Bollinger Band Walk Strength -0.80%
BB Squeeze + Upper Band Touch Range Contraction -0.80%
Upper Bollinger Band Touch Strength -0.80%
MACD Bullish Signal Line Cross Bullish -3.97%

Older signals for CYTK ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Biopharmaceutical Diseases Disease Neuroscience Anatomy Serious Diseases Heart Failure Amyotrophic Lateral Sclerosis Nervous System Astellas Pharma Treatment Of Heart Failure Treatment Of Serious Diseases
Is CYTK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.86
52 Week Low 5.75
Average Volume 437,743
200-Day Moving Average 8.327
50-Day Moving Average 10.5932
20-Day Moving Average 11.1125
10-Day Moving Average 11.193
Average True Range 0.4592
ADX 21.85
+DI 25.4387
-DI 17.6171
Chandelier Exit (Long, 3 ATRs ) 10.4824
Chandelier Exit (Short, 3 ATRs ) 12.0176
Upper Bollinger Band 11.5485
Lower Bollinger Band 10.6765
Percent B (%b) 0.53
BandWidth 7.847019
MACD Line 0.2366
MACD Signal Line 0.2596
MACD Histogram -0.023
Fundamentals Value
Market Cap 597.84 Million
Num Shares 53.7 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -32.76
Price-to-Sales 6.91
Price-to-Book 3.91
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.76
Resistance 3 (R3) 11.79 11.63 11.65
Resistance 2 (R2) 11.63 11.47 11.61 11.62
Resistance 1 (R1) 11.38 11.37 11.30 11.35 11.58
Pivot Point 11.22 11.22 11.18 11.20 11.22
Support 1 (S1) 10.97 11.06 10.89 10.94 10.70
Support 2 (S2) 10.81 10.96 10.79 10.66
Support 3 (S3) 10.56 10.81 10.63
Support 4 (S4) 10.53